Topic Highlight
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jul 14, 2016; 22(26): 5936-5949
Published online Jul 14, 2016. doi: 10.3748/wjg.v22.i26.5936
Table 1 Recent definitions of initial poor function and primary non function
Ref.IPFPNF
Broering et al[107]ALT or AST or GDH > 2000 IU/LNot-life sustaining graft leading to retransplantation or death within POD10
FFP substituted for > 5 d postoperatively
Nanashima et al[108]Two consecutive measurements within POD3:IPF-induced retransplantation or death
ALT or AST > 1500 IU/L
Heise et al[109]Scoring system based on ALT, AST, bile output, Prothrombin activity on POD1-3-7-14 (Berlin score ranging from 4 to 8) Berlin C (IPF): 7-8
Tekin et al[110]On POD7: AST > 1500 IU/L and PT > 20 sNot-life sustaining graft leading to retransplantation or death within POD7
Ben-Ari et al[111]AST or ALT > 2000 IU/L on POD2Not-life sustaining graft leading to retransplantationor death within POD10
INR > 1.6 on POD2-10
Bilirubin > 10 mg/dL on POD2-10
Kremers et al[112]ALT > 2500 IU/L
Glucose < 60 mg/dL
INR > 2.5
bile flow < 50 mL/d
Pokorny et al[113]On POD5: AST > 2500 IU/L or clotting support > 2 dNot-life sustaining graft leading to retransplantationor death within POD7
Monbaliu et al[114]Persisting encephalopathy
Irreversible metabolic acidosis
Profound hypoglicaemia
Severe coagulopathy
Insufficient bile production
Increased AST
Cieślak et al[115]Within POD1-7
AST or ALT > 2500 IU/L or Prothrombin index < 50%
Dhillon et al[116][(AST+ALT)/2] on POD2:IPF-induced retransplantationor death within POD7
< 285 IU/L: good function
285-986 IU/L: average function
> 986 IU/L: IPF
Nemes et al[117]On POD5: [Serum bilirubin (μmol/L)]/[Prothrombin (%)] > 1
Olthoff et al[81]On POD1-7, one within:
Bilirubin ≥ 10 mg/dL on POD7
INR ≥ 1.6 on POD7
ALT or AST > 2000 IU/L within POD7
Stockmann et al[59] and Lock et al[60]Two LiMax readouts during the first 24 h: LiMax = 60-120 μg/kg per hourTwo LiMax readouts during the first 24 h: LiMax < 60 μg/kg per hour
Máthé et al[118]Two consecutive measurements within POD3: ALT or AST > 1500 IU/LIPF-induced retransplantation or death
Table 2 Overview of the studies applying the mentioned techniques specifically about liver transplant
TechniqueStudyType (P/R)Primary end-point:SamplePODCut-off valueAUROC (95%CI)Sensitivity (%)Specificity (%)PPV (%)NPV (%)
ICG-PDROlmedilla et al[35]PEAD prediction172 LT: 31.9% HCC, 29.6% viral, 23.8% alcoholic110%/min0.967 (0.915-0991)100 (69-100)90.4 (84.7-94.6)40.00100.00
Levesque et al[42]PEAD prediction72 LT (including LDLT)0-512.85%/min90.097.0
Schneider et al[43]PGraft loss or patient death on POD3086 LT: 36% viral, 29% alcoholic712.3%/min0.729 (0.608-0.850)69.067.057.0077.00
Preoperative MELD + postoperative ICG-PDRKlinzing et al[45]PICU-LOS, mortality50 LT0 (< 6 h after ICU admission)MELD > 25,0.79100.059.0
ICG-PDR < 20%/min
ICG-PDR + INROlmedilla et al[44]P1-mo mortality or need for retransplantation within POD7332 LT (+77 validations)1ICG-PDR < 10%/min,0.76 (0.66-0.86)48 (31-66)95 (91-97)50 (32-68)94 (91-96)
INR > 2.2
LiMaxLock et al[58]PEAD requiring reintervention before POD2 or causing death/retransplantation within POD1499 LT: 32% alcoholic, 23% HCV064 μg/kg per hour0.960 (0.921-0.998)100 (60-100)92 (84-97)53 (27-78)100 (95-100)
143 μg/kg per hour0.992 (0.975-1.000)100 (31-100)100 (94-100)100 (31-100)100 (94-100)
Platelets countLesurtel et al[72]RSevere complications or 3-mo mortality257 LT: 38% HCV560 × 109/L58.061.0
Li et al[70]READ prediction234 LDLT: 45% HCC268 × 109/L0.67873.059.0
Factor VZulian et al[76]RGraft failure within POD90105 LT: 79.5% HCC, 76.2% HCV241.50%0.65042.987.935.3090.90
ASTRobertson et al[78]PGraft loss at POD901091 LT: 22% HCV32 cut-offs: 106.5 IU and 2744.5 IU0.739 (0.663-0.814)34.6299.45
BilirubinWagener et al[80]RGraft loss or death within POD90572 LT: 51.9% HCV26.55 mg/dL0.809 (0.742-0.877)72.570.4
Bilirubin, INR and transaminasesOlthoff et al[81]READ definition to predict mortality and graft loss300 LT7Bilirubin > 10 mg/dL, INR > 1.6, ALT or AST > 2000 IU/mL0.75-0.78
LactatesWu et al[84]PEAD prediction222 LT: 50% HBV, 41% HCC124.80%0.961 (0.948-0.974)95.588.9
IGF-1Bassanello et al[88]PExplore GH/IGF-1 axis changes during the perioperative course of LT15 LT: 52% viral, 20% alcoholic7n.a
Salso et al[90]R90-d patient survival30 LT: 40% HCV, 20% HBV1590 mUI/mL0.92086.087.0
Nicolini et al[89]P3-yr actual survival31 LT: 42.5% HCV15Normal values classified according to Immunolite 2000® system reference-ranges
MELDWagener et al[80]RGraft loss or mortality within POD90572 LT: 51.9% HCV5≥ 190.812 (0.739-0.886)
Toshima et al[91]RGraft loss or mortality within POD180217 LDLT: 47.9% HCV2≥ 190.77968.279.527.395.7
70.933100.074.931.0100.0
MELD lactateCardoso et al[92]PMortality within POD3058 LT: 43% HCV, 26% alcoholic1 h after surgery26.30.800
APACHE IVHu et al[119]RMortality195 LT1≥ 55.50.937 (0.892-0.981)85.291.160.597.5
SOFAWong et al[120]R3-mo mortality149 LT: 53% HBV7≥ 80.953 (0.902-1.000)95.091.0
CLIF-SOFAPan et al[104]R1-yr mortality323 LT: 62% HBV, 27% hepatoma, 26% HCV3> 80.808 (0.729-0.888)67.087.0
70.877 (0.813-0.941)64.095.0
MEAFPareja et al[106]READ definition ti predict 3-mo mortality874 LT (+200 validation)3> 8